These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 31448088)

  • 1. Triple-negative breast cancer: recent treatment advances.
    Bergin ART; Loi S
    F1000Res; 2019; 8():. PubMed ID: 31448088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of current progress in triple-negative breast cancer therapy.
    Shen M; Pan H; Chen Y; Xu YH; Yang W; Wu Z
    Open Med (Wars); 2020; 15(1):1143-1149. PubMed ID: 33336070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the systemic treatment of triple-negative breast cancer.
    Lebert JM; Lester R; Powell E; Seal M; McCarthy J
    Curr Oncol; 2018 Jun; 25(Suppl 1):S142-S150. PubMed ID: 29910657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
    Abahssain H; Souadka A; Alem R; Santoni M; Battelli N; Amela E; Lemaire A; Rodriguez J; Errihani H
    Curr Oncol; 2024 Jun; 31(7):3771-3782. PubMed ID: 39057150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancer: any closer to cracking the code?
    Peddi PF
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Triple-Negative Breast Cancer.
    Emens LA
    Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.